中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1552 records (took 0.029 seconds)

    ENHANCEMENT OF ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)
    2.
    发明申请
    ENHANCEMENT OF ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) 审中-公开

    公开(公告)号：WO2019101954A1

    公开(公告)日：2019-05-31

    申请号：PCT/EP2018/082427

    申请日：2018-11-23

    Applicant: IO BIOTECH APS

    Inventor： ANDERSEN, Mads, Hald

    IPC: A61P35/00 ,  A61K39/395 ,  C07K16/28 ,  A61K39/00

    CPC classification number: A61P35/00 ,  A61K39/00 ,  C07K16/2896 ,  C07K2317/732 ,  C07K2317/734 ,  A61K39/39558 ,  A61K2300/00 ,  A61K39/0011

    Abstract: The present invention relates to a method for increasing the therapeutic benefit of an antibody to a subject. The improved benefit is typically mediated by an increase in the antibody-dependent cell-mediated cytotoxicity (ADCC) effect of the antibody. The method comprises (a) administering to said subject an immunotherapeutic composition comprising a component of an immune system checkpoint, or an immunogenic fragment of said component; and (b) also administering said antibody to the subject. The increase in therapeutic benefit to the subject may be in respect of any disease for which the said antibody has a prophylactic or therapeutic effect. The disease may be cancer. The invention also relates to said immunotherapeutic composition and said antibody, and to kits comprising same.

    MEANS AND METHODS TO TREAT INFLAMMATION
    4.
    发明申请
    MEANS AND METHODS TO TREAT INFLAMMATION 审中-公开
    手段和方法治疗炎症

    公开(公告)号：WO2018073216A1

    公开(公告)日：2018-04-26

    申请号：PCT/EP2017/076427

    申请日：2017-10-17

    Applicant: VIB VZW ,  UNIVERSITEIT GENT

    Inventor： LIBERT, Claude ,  VANDENBROUCKE, Roosmarijn ,  STEELAND, Sophie

    IPC: C07K16/40 ,  C07K16/28 ,  A61K39/395 ,  A61K31/135

    CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2878 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/92

    Abstract: The present invention relates to a composition comprising MMP8 and TNFR1 inactivating antigen binding polypeptides, preferably antigen binding polypeptides comprising antibodies; it relates further to the use of such composition to treat inflammation, such as but not limited to systemic inflammatory response syndrome, sepsis, LPS induced inflammation, renal ischemia/reperfusion injury, ventilation induced lung injury, periodontal inflammation, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, ankylosing spondylitis, Lyme arthritis and osteoarthritis.

    Abstract translation: 本发明涉及包含MMP8和TNFR1失活抗原结合多肽的组合物，优选包含抗体的抗原结合多肽; 它进一步涉及这种组合物用于治疗炎症的用途，所述炎症例如但不限于全身性炎症反应综合征，败血症，LPS诱导的炎症，肾缺血/再灌注损伤，通气诱导的肺损伤，牙周炎症，类风湿性关节炎，炎性肠病 ，多发性硬化症，强直性脊柱炎，莱姆关节炎和骨关节炎。

    ANTI-CD39 ANTIBODIES
    5.
    发明申请
    ANTI-CD39 ANTIBODIES 审中-公开
    抗CD39抗体

    公开(公告)号：WO2018065552A1

    公开(公告)日：2018-04-12

    申请号：PCT/EP2017/075425

    申请日：2017-10-05

    Applicant: INNATE PHARMA

    Inventor： GAUTHIER, Laurent ,  ROUSSEL, Alain ,  AMIGUES, Béatrice

    IPC: C07K16/40 ,  A61K39/395

    CPC classification number: C07K16/2896 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/71

    Abstract: The present invention relates to antibodies that inhibit CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

    Abstract translation: 本发明涉及抑制CD39的抗体。 本发明还涉及产生这种化合物的细胞; 制备此类化合物的方法，以及其抗体，片段，变体和衍生物; 包含其的药物组合物; 使用该化合物诊断，治疗或预防疾病例如癌症的方法。

    ANTI-CD37 CHIMERIC ANTIGEN RECEPTORS AND IMMUNE CELLS EXPRESSING THEM
    8.
    发明申请
    ANTI-CD37 CHIMERIC ANTIGEN RECEPTORS AND IMMUNE CELLS EXPRESSING THEM 审中-公开
    抗CD37嵌合抗原受体和免疫细胞表达它们

    公开(公告)号：WO2017118745A1

    公开(公告)日：2017-07-13

    申请号：PCT/EP2017/050285

    申请日：2017-01-06

    Applicant: OSLO UNIVERSITETSSYKEHUS HF

    Inventor： SMELAND, Erlend ,  WALCHLI, Sebastien ,  KVALHEIM, Gunnar ,  HOLTE, Harald ,  MYKLEBUST, June, Helen ,  FUNDERUD, Steinar ,  SUSO, Else, Marit, Inderberg

    IPC: C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  A61K39/395 ,  C12N5/22 ,  C07K19/00 ,  A61P35/00

    CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/33

    Abstract: The present invention relates to nucleic acid molecules encoding chimeric antigen receptors (CARs) against the antigen CD37. The CARs disclosed herein have complementarity-determining regions (CDRs) derived from the potent monoclonal anti-CD37 antibody HH1, and may be used in immunotherapy to target cells expressing CD37. Such immunotherapy has a particular use in the treatment of B-cell cancers. The CARs of the present invention are highly functional in the redirection of immune cells to kill CD37+ cells, and include humanised CARs of particular use in medical therapy. The present invention also includes vectors comprising the above-described nucleic acid molecules, immune effector cells expressing the aforementioned CARs and the use of such immune effector cells in therapy, particularly adoptive transfer therapy, for cancer, including B-cell malignancies.

    Abstract translation: 编码针对抗原CD37的嵌合抗原受体（CAR）的核酸分子本发明涉及编码针对抗原CD37的嵌合抗原受体（CAR）的核酸分子。 本文公开的CAR具有源自有效单克隆抗CD37抗体HH1的互补决定区（CDR），并且可用于免疫疗法以靶向表达CD37的细胞。 这种免疫疗法在B细胞癌的治疗中具有特别的用途。 本发明的CAR在免疫细胞重新定向以杀死CD37 +细胞方面具有高度的功能，并且包括在医学治疗中特定用途的人源化CAR。 本发明还包括包含上述核酸分子，表达上述CAR的免疫效应细胞的载体以及这种免疫效应细胞在治疗，特别是过继转移治疗中用于癌症，包括B细胞恶性肿瘤的用途。

    BISPECIFIC ANTIBODIES TARGETING HUMAN CD73
    9.
    发明申请
    BISPECIFIC ANTIBODIES TARGETING HUMAN CD73 审中-公开
    靶向人类CD73的双特异性抗体

    公开(公告)号：WO2017118613A1

    公开(公告)日：2017-07-13

    申请号：PCT/EP2017/050003

    申请日：2017-01-02

    Applicant: SYDDANSK UNIVERSITET

    Inventor： DITZEL, Henrik ,  GAMMELGAARD, Odd Lilleng

    IPC: C07K16/28

    CPC classification number: C07K16/2896 ,  C07K2317/31 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77

    Abstract: The present invention relates to a bispecific antibody targeting CD73. In particular, the present invention relates to a bispecific antibody targeting different epitopes on CD73 or a bispecific antibody targeting an epitope on CD73 and an epitope on a different antigen.

    Abstract translation: 本发明涉及靶向CD73的双特异性抗体。 具体而言，本发明涉及靶向CD73上的不同表位的双特异性抗体或靶向CD73上的表位和不同抗原上的表位的双特异性抗体。

    PREDICTING RESPONSE TO CANCER TREATMENT WITH FGFR2 INHIBITORS
    10.
    发明申请
    PREDICTING RESPONSE TO CANCER TREATMENT WITH FGFR2 INHIBITORS 审中-公开
    预测FGFR2抑制剂对肿瘤治疗的反应

    公开(公告)号：WO2017091580A1

    公开(公告)日：2017-06-01

    申请号：PCT/US2016/063340

    申请日：2016-11-22

    Applicant: FIVE PRIME THERAPEUTICS, INC.

    Inventor： PIERCE, Kristen ,  POWERS, Janine ,  PALENCIA, Servando ,  SIKORSKI, Robert ,  GHODDUSI, Majid ,  KRISHNAN, Kartik

    IPC: C07K16/28 ,  G01N33/574

    CPC classification number: C07K16/2863 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55 ,  C07K16/2818 ,  C07K16/2896 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3069 ,  C07K16/3084 ,  C07K2317/34 ,  C07K2317/41 ,  G01N33/5091 ,  G01N33/57407 ,  G01N33/57446 ,  G01N33/57492 ,  G01N2333/71 ,  G01N2800/52

    Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides. This application also provides methods of predicting response to treatment of cancer, such as bladder or gastric cancer, with FGFR2 inhibitors by determining FGFR2 overexpression and/or gene amplification in tumor cells of cancer subjects before treatment with FGFR2 inhibitors either alone or in combination with immune stimulating agents.

    Abstract translation: 本文提供成纤维细胞生长因子受体2（FGFR2）抑制剂在癌症治疗中的用途，在某些情况下与免疫刺激剂例如PD-1或PD-L1的抑制剂组合。 在一些实施方案中，FGFR2抑制剂可以包含FGFR2抗体或FGFR2胞外域（ECD）多肽或包含FGFR2ECD和融合伴侣的FGFR2ECD融合分子。 在一些实施方案中，PD-1 / PD-L1抑制剂可以包含抗PD-1抗体，例如与PD-1或PD-L1结合并抑制这些蛋白之间以及PD-1融合蛋白或 多肽。 本申请还提供了用FGFR2抑制剂预测对治疗癌症例如膀胱癌或胃癌的反应的方法，通过确定FGFR2过表达和/或癌症受试者的肿瘤细胞中的基因扩增，然后单独或与FGFR2联合使用FGFR2抑制剂 刺激剂。

Patent Agency Ranking